GAMMA Investing LLC raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 4,005.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,230 shares of the specialty pharmaceutical company's stock after buying an additional 42,177 shares during the period. GAMMA Investing LLC owned approximately 0.08% of Supernus Pharmaceuticals worth $1,320,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of SUPN. Raiffeisen Bank International AG purchased a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $25,000. Versant Capital Management Inc raised its holdings in Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 1,109 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $42,000. Smartleaf Asset Management LLC lifted its stake in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after acquiring an additional 870 shares during the last quarter. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth $52,000.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on SUPN. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th.
Check Out Our Latest Stock Analysis on SUPN
Supernus Pharmaceuticals Price Performance
Shares of SUPN traded up $0.41 during midday trading on Monday, reaching $32.44. 1,197,330 shares of the stock were exchanged, compared to its average volume of 483,608. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.55 and a twelve month high of $40.28. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of 30.32 and a beta of 0.71. The business's 50-day moving average price is $32.02 and its 200 day moving average price is $34.32.
Supernus Pharmaceuticals Company Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
See Also
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
